Literature DB >> 10664829

Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans.

G Gerra1, A Zaimovic, M Ferri, U Zambelli, M Timpano, E Neri, G F Marzocchi, R Delsignore, F Brambilla.   

Abstract

BACKGROUND: Fifteen (+/-)3,4-Methylenedioxymethamphetamine (MDMA) users, who did not show other drug dependencies or prolonged alcohol abuse, and 15 control subjects were included in the study.
METHODS: Prolactin (PRL) and cortisol (CORT) responses to the serotonergic agonist d-fenfluramine (D-fen), clinical psychobehavioral changes, and psychometric measures were evaluated 3 weeks and then 12 months after MDMA discontinuation.
RESULTS: MDMA users showed significantly reduced PRL and CORT responses in comparison with control subjects at 3 weeks (respectively, p < .001; p < .005). The responses of PRL to D-fen were unmodified at 12 months after prolonged abstinence and were significantly reduced in comparison with controls (p < .001). In contrast, CORT responses in MDMA users were restored after 12 months of abstinence, with significantly higher responses to D-fen, in comparison with 3-week responses (p < .05). MDMA users' high scores on the Novelty Seeking (NS) scale on the Tridimensional Personality Questionnaire (TPQ) appeared unchanged by long-term abstinence. In contrast, Buss Durkee Hostility Inventory (BDHI) (Buss and Durkee 1957) direct and guilt scores decreased significantly after 12 months of abstinence. PRL AUCs at 12 months were inversely correlated with the measures of MDMA exposure (r = -.538).
CONCLUSIONS: Our data indicate long-lasting 5-HT system impairment in abstinent MDMA users although the hypothesis of serotonergic changes attributable to a premorbid condition cannot be excluded. CORT restored responses to D-fen at 12 months, and the correlation of neuroendocrine changes with MDMA exposure suggest that the neuroendocrine impairment may be due to a partially reversible neurotoxic action of MDMA on the human brain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10664829     DOI: 10.1016/s0006-3223(99)00180-8

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  23 in total

Review 1.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

Review 2.  Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.

Authors:  Tomas Palomo; R M Kostrzewa; R J Beninger; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

3.  The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.

Authors:  Maartje M L De Win; Gerry Jager; Hylke K E Vervaeke; Thelma Schilt; Liesbeth Reneman; Jan Booij; Frank C Verhulst; Gerard J Den Heeten; Nick F Ramsey; Dirk J Korf; Wim Van den Brink
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

Review 4.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

5.  Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users.

Authors:  Una D McCann; Robert R Edwards; Michael T Smith; Kristen Kelley; Michael Wilson; Francis Sgambati; George Ricaurte
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

6.  Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

Authors:  Una D McCann; Francis P Sgambati; Alan R Schwartz; George A Ricaurte
Journal:  Neurology       Date:  2009-12-02       Impact factor: 9.910

7.  Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users.

Authors:  Karen L Hanson; Monica Luciana; Kristin Sullwold
Journal:  Drug Alcohol Depend       Date:  2008-04-01       Impact factor: 4.492

8.  Relationship between ecstasy use and depression: a study controlling for poly-drug use.

Authors:  Jonathan P Roiser; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-12-03       Impact factor: 4.530

9.  Tri-city study of Ecstasy use problems: a latent class analysis.

Authors:  Lawrence M Scheier; Arbi Ben Abdallah; James A Inciardi; Jan Copeland; Linda B Cottler
Journal:  Drug Alcohol Depend       Date:  2008-07-31       Impact factor: 4.492

10.  Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender.

Authors:  Maartje M L de Win; Liesbeth Reneman; Johannes B Reitsma; Gerard J den Heeten; Jan Booij; Wim van den Brink
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.